Companies › Lanyue Biotech (Hangzhou)
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout May 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SKG0201 Injection rAAV vector-based gene therapy delivering SMN1 gene | SMN1 | Phase 1 | Spinal Muscular Atrophy 1 | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07554924 | SKG0201 Injection | Phase 1 | Spinal Muscular Atrophy 1 | Neurology | May 2029 |
Novartis Gemma Biotherapeutics GeneCradle Biocad Lantu Biopharma
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.